60 Degrees Pharmaceuticals, Inc. (SXTP) Stock

60 Degrees Pharmaceuticals, Inc. (SXTP) is a Healthcare stock trading at $1.11 (as of 2026-08-21), with a market capitalization of $2.95M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

60 Degrees Pharmaceuticals, Inc. develops and commercializes therapies aimed at preventing and treating infectious diseases in the United States. Its products and clinical programs include Arakoda for malaria prevention, tafenoquine (including trials for COVID-19, babesiosis, and several other indications), and celgosivir for Zika, respiratory viruses, and dengue, including a patent licensing arrangement with Tufts Medical Center.

Understand 60 Degrees Pharmaceuticals, Inc.: how it makes money

60 Degrees Pharmaceuticals develops and commercializes specialty therapies for infectious diseases, including Arakoda for malaria prevention, and it also advances drug candidates such as tafenoquine (Arakoda regimen) and others through clinical trials.

Because the company is both selling at least one marketed product (Arakoda) and running multiple clinical-stage infectious disease programs, its profit model is tied to how well near-term product commercialization performs while later-stage trials progress toward potential future approvals.

Business quality (Weak): Limited investor-facing detail is provided here, with no official reportable segments or operational KPIs listed in the supplied facts, so it is harder to pinpoint what drives operating performance beyond commercialization and clinical-stage progress.

Bull case

  • Multiple infectious disease programs: Beyond Arakoda for malaria prevention, the company is developing tafenoquine (Arakoda regimen) for COVID-19 (Phase IIb) and is also studying tafenoquine in Phase IIa for babesiosis, fungal pneumonias, and candidiasis, with Celgosivir in trials for Zika and other respiratory viruses.
  • At least one therapy is commercialized: Arakoda is described as an offered malaria preventative treatment, which can provide a commercial revenue stream while pipeline assets mature.

Bear case

  • Highly negative operating profitability: For the quarter ended 2026-03-31, the dataset shows an operating margin of -1292.5%, indicating substantial operating losses.
  • Clinical execution risk: Several key programs are in clinical phases (Phase IIA and Phase IIb described), which means outcomes and timelines may change and may not lead to approvals.
Valuation — source: SEC EDGAR (first-party)
Price$1.11
Market Cap$2.95M
Price / Book1.17
Price / Sales3.04
FCF Yield-534.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.01M
Net Margin-732.5%
Revenue Growth (YoY)65.5%
EPS Growth (YoY)-36.8%
FCF Growth (YoY)21.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-15.51 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderKathmere Capital Management, LLC ($253195.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGeoffrey Stuart Dow
Employees3
CountryUS
IPO Date2023-07-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • FibroBiologics, Inc. Common Stock (FBLG)
  • GRI Bio, Inc. (GRI)
  • Genprex, Inc. (GNPX)
  • Artelo Biosciences, Inc. (ARTL)
  • Ernexa Therapeutics Inc. (ERNA)
  • Nexentis Technologies Inc. (NXTS)
  • Onconetix, Inc. (ONCO)
  • HCW Biologics Inc. (HCWB)
SXTP earnings history · SXTP institutional & insider holders · SXTP KPIs & operating metrics · SXTP financials · SXTP investor presentations & press releases · SXTP SEC filings · SXTP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.